Citation
- Authors: Venkatraman, G., Benesch, M. G., Tang, X., Dewald, J., McMullen, T. P., Brindley, D. N.
- Year: 2015
- Journal: FASEB J 29 772-85
- Applications: in vitro / siRNA / INTERFERin
- Cell type: MDA-MB-231
Description: Human breast adenocarcinoma cells
Known as: MDAMB231
Method
50 nM of siRNA.
Abstract
The present work elucidates novel mechanisms for lysophosphatidate (LPA)-induced chemoresistance using human breast, lung, liver, and thyroid cancer cells. LPA (0.5-10 muM) increased Nrf2 transcription factor stability and nuclear localization by 70%, whereas doxorubicin alone had no significant effect. This study provides the first evidence that LPA increases antioxidant gene and multidrug-resistant transporter expression. Blocking this aspect of LPA signaling provides a novel strategy for improving chemotherapy.